Pharmacokinetics of long-circulating liposomes
References (91)
- et al.
Liposomes in the treatment of malignancy: a clinical perspective
Crit. Rev. Oncol. Hematol.
(1992) Liposomes as carriers of antigens and adjuvants
J. Immunol. Methods
(1991)- et al.
Liposomes as agents of DNA transfer
Biochim. Biophys. Acta
(1993) - et al.
Large unilamellar liposomes with low uptake into the reticuloendothelial system
FEBS Lett.
(1987) The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system
Adv. Drug Deliv. Rev.
(1994)- et al.
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
FEBS Lett.
(1990) - et al.
Liposomes for the sustained drug release in vivo
Biochim. Biophys. Acta
(1990) - et al.
Liposomes containing synthetic lipid derivatives of poly(ethyleneglycol) show prolonged circulation half-lives in vivo
Biochim. Biophys. Acta
(1991) - et al.
Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles
Biochim. Biophys. Acta
(1991) - et al.
Pharmacokinetics of stealth versus conventional liposomes: effect of dose
Biochim. Biophys. Acta
(1991)
Preparation of lipid vesicles containing high levels of radioactive cations
Anal. Biochem.
Encapsulation, with high efficiency, of radioactive metal ions in liposomes
Biochim. Biophys. Acta
125I labelled inulin: a convenient marker for deposition of liposomal contents in vivo
Biochem. Biophys. Res. Commun.
The uptake of liposome-entrapped 125I-labelled poly-vinylpyrrolidone by rat jejunum in vitro
Biochim. Biophys. Acta
Liposome disposition in vivo. III. Dose and vesicle-size effects
Biochim. Biophys. Acta
In vivo fate of large unilamellar sphingomyelin-cholesterol liposomes after intraperitoneal and intravenous injection into rats
Biochim. Biophys. Acta
Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes in injection
Biochim. Biophys. Acta
Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues
Biochim. Biophys. Acta
Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavourable for immunoliposomes binding to target
Biochim. Biophys. Acta
Amphipathic poly(ethylene glycol) 5000-stabilized dioleoylphosphatidylethanolamine liposomes accumulate in spleen
Biochim. Biophys. Acta
Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes
Biochim. Biophys Acta
Large liposomes containing ganglioside GM1 accumulate effectively in spleen
Biochim. Biophys. Acta
Proteins and peptides bound to long-circulating liposomes
Biochim. Biophys. Acta
Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoylphosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol)
Biochim. Biophys. Acta
Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo
FEBS Lett.
Factors influencing the retention and chemical stability of poly(ethyleneglycol)-lipid conjugates incorporated into large unilamellar liposomes
Biochim. Biophys. Acta
Versatility in lipid composition showing prolonged circulation with sterically stabilized liposomes
Biochim. Biophys. Acta
Sterically stabilized liposomes
Biochim. Biophys. Acta
Effects of particle size and charge on the clearance of liposomes and liposome-encapsulated drugs
Biochem. Biophys. Res. Commun.
Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes
Biochim. Biophys. Acta
Interaction of positively charged liposomes with blood: implications for their applications in vivo
Biochim. Biophys. Acta
The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade
Biochim. Biophys. Acta
Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue
Biochim. Biophys. Acta
Liposomes as carriers of cancer chemotherapy: current status and future prospects
Drugs
The use of liposomes as drug carriers in ophthalmology
Crit. Rev. Ther. Drug Carrier Syst.
Liposomes as carriers of antimicrobial agents or immunomodulatory agents in the treatment of infections
Eur. J. Clin. Microbiol. Infect. Dis.
The role of liposomes in diagnostic imaging
Radiology
Liposome pharmacokinetics
Liposomes: from Physics to Applications
Glucuronate-modified liposomes with prolonged circulation time
Chem. Pharm. Bull. (Tokyo)
Design of liposomes for circumventing the reticuloendothelial cells
Glycobiology
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy
An improved method for in vivo tracing and imaging of liposomes using a gallium 67-desferoximine complex
J. Liposome Res.
Preclinical and clinical experience with a doxorubicin-liposome preparation
J. Liposome Res.
Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times
J. Natl. Cancer Inst.
Cited by (277)
Research on the preparation process of the cytarabine/daunorubicin dual-encapsulation liposome and its physicochemical properties and performances in vitro/vivo
2023, International Journal of PharmaceuticsStealth and pseudo-stealth nanocarriers
2023, Advanced Drug Delivery ReviewsRecent progress in synthesis of nano based liposomal drug delivery systems: A glance to their medicinal applications
2023, Results in Surfaces and InterfacesExpanding therapeutic strategies for intracellular bacterial infections through conjugates of apoptotic body–antimicrobial peptides
2023, Drug Discovery TodayCitation Excerpt :However, the most relevant challenges regarding the design of new AMPs for treating intracellular infections are their limited cell specificity, bioavailability, and delivery. Regardless of the type of pathogen to be treated, the vehicle used for administration might be more crucial than the peptide itself for successful clearance of infection.6,7 Therefore, such vehicles act as ‘trojan horses’ loaded with bioactive molecules for therapeutic purposes.
Extracellular vesicles as a drug delivery system: A systematic review of preclinical studies
2021, Advanced Drug Delivery ReviewsCitation Excerpt :To circumvent these challenges, a broad range of synthetic delivery vehicles (liposomes, lipid nanoparticles, polymeric micelles, inorganic nanoparticles, dendrimers, etc.) have been developed in the last few decades with some of them already clinically approved. The main concept of a drug delivery vehicle is that the tissue distribution and the body clearance are governed by the characteristics of the vehicle instead of those of the drug itself [230–232]. Out of the available spectrum of all nanoparticles, the most successful delivery vehicles up to date, with the highest number of clinical approvals on the market, are the liposomes.